The bill adds a new sentence to section 1861(n) of the Social Security Act so that external infusion pumps and associated non‑self‑administrable home infusion drugs (and supplies) can be treated as meeting the durable medical equipment (DME) “appropriate for use in the home” requirement when three conditions are met: the FDA prescribing information requires professional administration; a qualified home infusion therapy supplier administers or supervises administration in the patient’s home; and the drug is infused at least 12 times per year or at rates that, in CMS’s view, require an external pump. Implementation is tied to a statutory delay: the rule applies starting the first calendar quarter beginning one year after enactment.
The bill also directs HHS to ensure Medicare patients receive a cost‑sharing comparison between electing home infusion therapy and receiving infusion drugs in other care settings. The change would expand Medicare’s reimbursable DME and shift clinical and billing activity into the home, creating new opportunities for suppliers and manufacturers but also raising questions about program costs, clinical oversight, supplier standards, and the regulatory mechanics the Secretary will need to issue.
At a Glance
What It Does
The bill amends 42 U.S.C. §1861(n) to allow external infusion pumps and associated non‑self‑administerable infusion drugs/supplies to qualify as meeting the DME home‑use requirement when three statutory criteria are satisfied, rather than being excluded due to an existing home‑use test. It sets an implementation clock: coverage begins the first calendar quarter starting one year after enactment.
Who It Affects
Medicare fee‑for‑service beneficiaries requiring infusion therapy, home infusion therapy suppliers, manufacturers of external infusion pumps and related supplies, outpatient infusion centers and hospitals that currently furnish and bill for infusion services, and CMS operations staff who must implement new rules and beneficiary notices.
Why It Matters
This creates a statutory pathway to shift non‑self‑administered infusion care into patients’ homes by treating pump systems as home‑appropriate DME under defined conditions. That changes reimbursement access, creates a market incentive for home infusion suppliers and devices makers, and forces CMS to reconcile clinical supervision, supplier qualifications, and cost‑sharing disclosures with program integrity.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill inserts a targeted amendment into the Medicare statute so certain external infusion pumps and the drugs they deliver can be treated as home‑appropriate durable medical equipment even if the pumps would otherwise fail the current regulatory “appropriate for use in the home” test. Rather than broadly redefining DME, it creates a conditional exception: coverage follows when the drug’s FDA label calls for administration by or under the supervision of a health professional; a qualified home infusion therapy supplier actually administers or supervises the infusion in the patient’s residence; and the therapy meets a frequency or infusion‑rate threshold in the statute.
Operationally, that means CMS would be required to recognize these pumps and associated drugs as meeting the home‑use DME requirement for Medicare billing once the three criteria are met. The statute establishes a delayed effective date tied to the first calendar quarter starting one year after enactment, which gives CMS time to issue regulatory guidance and suppliers time to adjust.
The bill references definitional cross‑references (for example, items called out as subsection (iii)(3)(B)/(C)/(D)), indicating the statute expects certain definitional terms—"qualified home infusion therapy supplier," "home," and "home infusion drug"—to be read together with the amendment or filled in by regulation.In addition to changing coverage eligibility, the bill requires the Secretary to ensure Medicare beneficiaries receive a clear cost‑sharing notification that compares out‑of‑pocket costs for receiving infusion therapy at home versus other settings. That is an explicit consumer‑information requirement rather than a payment rule; it will affect CMS beneficiary communications, potentially Medicare Summary Notices and supplier disclosures, but does not itself set payment rates or adjust benefit design.
The Five Things You Need to Know
The bill amends section 1861(n) of the Social Security Act to add a new sentence allowing specified external pumps and associated home infusion drugs/supplies to be treated as meeting the DME “appropriate for use in the home” requirement.
Coverage under the amendment becomes effective the first calendar quarter beginning one year after the date of enactment—creating a statutory implementation delay for CMS.
Three statutory criteria must be met for the exception to apply: (1) the FDA‑approved prescribing information directs professional administration or supervision; (2) a “qualified home infusion therapy supplier” administers or supervises the infusion at home; and (3) the drug is infused at least 12 times per year (IV or subcutaneous) or at rates that CMS deems to require an external pump.
By treating the pump and associated supplies as meeting the home‑use DME test, the bill opens the door to DME billing for devices and supplies that otherwise would be excluded under the existing regulatory home‑use standard.
The Secretary must ensure patients are notified about the cost‑sharing implications of choosing home infusion therapy versus receiving infusion drugs in other settings of care, but the bill does not set the content or format of that comparison.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
This single‑line provision names the measure the “Joe Fiandra Access to Home Infusion Act of 2025.” It has no operational effect but is the statutory caption that will appear on the enacted law.
Conditional exception to the DME home‑use requirement
The core change is a one‑sentence addition to 42 U.S.C. §1861(n). That sentence creates a statutory exception so that an external infusion pump and associated home infusion drug or supplies that would not satisfy the existing regulatory ‘appropriate for use in the home’ test can nevertheless be treated as meeting that test when the three enumerated criteria are satisfied. Practically, this is a targeted statutory override of the regulatory home‑use standard that will require CMS to adjust coverage determinations and billing guidance for DME and related drug supply claims.
FDA label, supplier supervision, and frequency/rate thresholds
The amendment sets out three distinct gates: (1) the drug’s FDA‑approved prescribing information must instruct that the drug be administered by or under supervision of a health care professional; (2) a ‘qualified home infusion therapy supplier’ must administer or supervise the infusion in the patient’s home; and (3) the prescribing information must indicate the drug is infused at least 12 times per year (IV or subcutaneous) or at infusion rates that the Secretary determines require an external pump. Each gate points to different decision‑makers: FDA determines label content; CMS (and possibly statuteally defined supplier criteria) will determine qualified suppliers and the Secretary will set the infusion‑rate threshold.
Beneficiary cost‑sharing notification
This provision directs the Secretary to ensure patients receive notice comparing cost sharing for home infusion therapy with other settings where infusion drugs are furnished. The bill does not specify the notice vehicle, timing, or the precise cost elements to be compared; those operational choices will fall to CMS rulemaking, beneficiary communications teams, and possibly subsequent guidance to suppliers.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare beneficiaries requiring frequent infusion therapy — The change creates a pathway to receive professionally supervised, non‑self‑administered infusions at home, reducing travel and potential exposure associated with facility visits.
- Qualified home infusion therapy suppliers — Suppliers that meet CMS’s eventual qualification criteria gain access to billable DME‑related services and supplies tied to pump use, expanding potential revenue streams.
- Manufacturers of external infusion pumps and related supplies — Treating pumps as home‑appropriate DME under specified conditions enlarges the addressable Medicare market for devices and consumables.
- Rural and mobility‑limited patients — Patients who live far from infusion centers or have difficulty traveling may gain clinically supervised home options that were previously unavailable under Medicare.
Who Bears the Cost
- Medicare program finances — Expanding coverage eligibility for pumps and associated supplies is likely to increase Medicare spending, at least initially, as home infusion utilization rises and CMS sets payment policies.
- Hospitals and outpatient infusion centers — Facility‑based infusion providers may see reduced volumes and revenue if patients shift to home infusion under the new coverage path.
- CMS and HHS operational staff — The agency must define ‘qualified’ suppliers, set infusion‑rate criteria, issue coverage and billing instructions, and design beneficiary cost‑sharing notices, creating administrative workload and potential resource needs.
- Home infusion suppliers and small providers — New qualification, documentation, and supervision requirements may impose compliance costs and operational changes, particularly for smaller suppliers that must meet as‑yet unspecified standards.
Key Issues
The Core Tension
The central dilemma is access versus oversight: the bill expands beneficiaries’ ability to receive professionally supervised infusions at home—improving convenience and potentially reducing facility use—while creating risks for higher Medicare spending and patient safety unless CMS establishes clear supplier qualifications, tight medical‑necessity criteria, and robust program integrity controls.
The bill is concise and creates a statutory exception without spelling out important operational definitions and standards. It references “qualified home infusion therapy supplier,” “home infusion drug,” and the patient’s “home” by cross reference to subsection (iii)(3)(B)/(C)/(D), but the text provided here does not include those definitions.
Absent explicit statutory definitions, CMS must either find or create regulatory definitions, or rely on existing program guidance, which creates uncertainty about supplier accreditation, staffing, nurse‑visit frequency, and documentation required to demonstrate that a supplier ‘administers or supervises’ treatment in a safe manner.
Another tension is between access and program cost and oversight. Allowing pumps and associated supplies to be treated as home‑appropriate DME when professional supervision occurs may lower site‑of‑care costs and improve convenience for beneficiaries; at the same time, it can increase utilization and device/supply spending and invite upcoding or inappropriate placement of care if supplier qualifications and medical necessity standards are not tightly specified.
The statutory frequency threshold (at least 12 infusions per year) is a blunt instrument: it captures recurring therapies but does not distinguish clinical complexity, patient frailty, or the varying risk profiles of different drugs. Finally, the cost‑sharing notification requirement pushes CMS to inform patients but does not address how clinician incentives, MA plan rules, or state scope‑of‑practice laws interact with the new coverage pathway.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.